Small Cap Feast

Small Cap Feast – 28 February 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 908

Total number of AIM Companies trading: 837*
* As at 27 February 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 27 February 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 161*

Total number of Standard List Companies trading: 142*
* As at 27 February 2019

Dish of the Day:

Digitalbox (DBOX.L), formerly Polemos PLC, has joined AIM today after acquiring Digitalbox Publishing (Holdings) Limited and Mashed Productions Limited which constitutes a Reverse Takeover.

Off the Menu:

No Leavers Today

Dish of the Day:

Proton Partners,  the holding company of a group committed to providing innovative cancer care of the highest quality, has joined the NEX Exchange Growth Market today.

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

DWF, a global legal business,  expects to raise primary gross proceeds of approximately £75m. Due March

AIM

United Oil & Gas (UOG.L) an oil and gas exploration and development company brought to the Official List (Standard Segment) in July 2017 by way of a reverse takeover of Senterra Energy plc. No capital to be raised, expected market cap of £17m and expected 1 March

Techniplas –global  producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient.  FYDec17 rev $515m.

Breakfast Buffet

FireAngel Safety Tech (FA..L) 26p £11.02m

One of Europe’s leading developers and suppliers of home safety products, announced that, following the introduction of new legislation in Scotland, it has signed an agreement to supply mains and battery-powered smoke and heat alarms to another housing association 

The Company will supply West of Scotland Housing Association with a combination of interlinked mains and battery-powered products to around 3,500 homes.

This contract win follows the requirement for greater safety standards introduced in the Housing (Scotland) Act, which came into force on 1 Feb 2019. This requires all homes to have a smoke alarm fitted in the living room or lounge and in circulation spaces such as hallways, landings and kitchens and all fitted alarms are required to be interlinked so they can be heard throughout the property.

 

Conroy Gold & Natural Resources (CGNR.L) 8.88p £2.1m

HY Nov 18 Results.

Excellent drill results from extended programme at Clontibret; 1,768 metres completed.

Updated Exploration Target of 8.8m ounces of gold:

In only the three major gold targets – Clontibret, Clay Lake and Glenish – and excluding the defined gold resource of over 500k  ounces at Clontibret

Clontibret: 

Gold lodes intercepted with excellent grades – up to 24g/t. New area of bedrock gold mineralisation discovered between the Clontibret gold deposit and the Corcaskea gold target

Clay Lake:

Gold intersection of over 150 metres at 0.3g/t gold. The intersection at a downhole depth of 252 metres is the deepest to date

Finances:

Placing  to raise £0.5m completed. The loss after taxation for the half-year ended 30 Nov 2018 was €0.29m (six-month period ended 30 Nov 2017: loss €0.46m)

 

Mercia Technologies (MERC.L) 38.3p £114m

The national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential from the UK regions, today announced that its portfolio company, Oxford Genetics Limited, has successfully negotiated six licensing deals for its scalable gene therapy manufacturing technologies in the last twelve months.

Projects of note include;

A licence agreement with Aldevron, a leading US service provider, to bring to market the Lentiviral Plasmids created by Oxford Genetics.

A collaboration project with Sphere Fluidics to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cells.

Mercia holds a 40.5% direct equity stake in the business and has worked with the team at Oxford Genetics since 2012.

 

Sareum Holdings* (SAR.L) 0.68p £17.26m

Sareum Holdings, the specialist small molecule drug development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, announced late yesterday that an abstract reporting preclinical data for SRA737, its Chk1 inhibitor, plus low dose gemcitabine (LDG), in combination with immunotherapy, has been selected for a late-breaking oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, to be held in Atlanta, GA, USA from 29 March to 3 April 2019.

A late-breaking abstract details highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline. Only those abstracts that are deemed to be of high scientific priority will be accepted for presentation at the meeting.

 

Intercede Group (IGP.L) 20.7p £10.65m

The “specialist in digital identity, credential management and secure mobility, announced the first sale of its MyID credential management software to an end customer in the region of SE Asia.

An order totalling $0.5m has been received from a new Partner with offices in Singapore, Hong Kong and Malaysia, that does business throughout the region. The order includes software licenses, associated Support & Maintenance, Development and Professional Services; some of which will be recognised as revenue beyond the current financial year.

It is also anticipated that this first contract will lead onto further business in the region in future years.”

 

Ricardo (RCDO.L) 604p £323.11m

HYDec18 Results. Ricardo plc is a global engineering, technical, environmental and strategic consultancy business, which also manufactures and assembles low-volume, high-quality and high-performance products.

Order intake good at £202m, compared to £238m in HY 2017/18;

Order book increased to £302m, up £7m on June 2018;

Revenue up 4% to £188m on HY 2017/18;

Underlying PBT up 1% to £15.3m on HY 2017/18;

Interim dividend increased by 4% to 6p from 5.75p.

“Acknowledging the uncertain economic climate, we remain positive due to a good order book and diverse pipeline, the recently signed long-term McLaren programme, and deliveries of ABS kits now underway.”

 

MyCelx (MYX.L) 240p £46.08m

Proposed $1.8m placing by the clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide traded at 230p. C.6% discount to yesterday’s close.

The Fundraising is being undertaken in order to sustain the recent momentum delivered by the Company and to remove the key hurdles to faster growth in the Company’s core markets. The net proceeds of the Fundraising will be used to fund additional equipment inventory in Saudi Arabia to meet the demand for rental fleet solutions.

 

European Metals (EMH.L) 17.75p £26.7m

Recent results from its current eight core-hole resource drilling programme at the Cinovec Project.

Hole CIS-14 returned 67m averaging 0.43% Li2O (incl. 3m @ 0.99% Li2O and 0.18% Sn); 8m @ 0.67% Li2O and 0.20% Sn (incl. 4.15m @ 1.00% Li2O and 0.35% Sn); 8m @ 0.21% Sn, 4m @ 0.39% Sn; and 3m @ 0.20% Sn

“The results of this programme have either been in line with, or exceeded, our expectations particularly with regard to the tin intercepts. I look forward to reporting the results of our lithium hydroxide production work, and the projected impacts upon the economics of the project over the next few weeks.”

 

Plant Health Care (PHC.L) 9.6p £16.59m

Update on the product pipeline in its New Technology business, following the recent strategic review of the prospects for PREtec (the Company’s novel Plant Response Elicitor Technology platform):

Moving lead PREtec peptides forward into fast-track product development, anticipated entry into first markets as early as 2021.

Addressing markets worth in excess of $5bn.

Seven companies have ongoing evaluations of   PREtec or are planning to initiate field evaluations in 2019.

The Company intends to sell some products directly to distributors, to reach market more rapidly and deliver  higher margins for the Company.  Discussions underway in the US and Brazil.

 

Spire Healthcare (SPI.L) 127p £510.58m

FY Dec18 results from  the independent UK hospital group. Revenue flat at £931.1m

Growth in PMI revenue of 1.5% and Self-pay of 8.7% offset by a reduction in NHS revenue of 7.2%

EBITDA  £119.4m (2017: £150m)

New hospitals in Manchester, Nottingham and St Anthony’s reported combined positive EBITDA for the first time

Adjusted PBT £27.5m (2017: £57.9m)

Divi flat at 2.5p.  Net debt decreased to £453.8m, with covenant leverage at 3.67x EBITDA at year end, revised to 3.27x going forwards following covenant amendment

After a difficult year, in 2019 we expect a return to modest revenue growth, offset by mix and the full year effect of investments in quality. This outlook reflects a measured approach whilst the NHS remains an uncertain market.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.